[Approaches to treatment for gynecologic malignancies--particularly on hyperthermic treatment].
Diagnosis and treatment at the early stage are bases of therapy for cancer. Great efforts have been made from this policy also in treatment of cervical cancer most frequently encountered in gynecology. Recent progress of cytodiagnosis and prevalence of mass screening enable us to more frequently detect intraepithelial lesions, such as dysplasia, CIS, and early cancer at Stage Ia, and are about to achieve the initial object with 5-years surgical cure rate close to 100%. For the last decade, however, detection rates of cancers at Stages III and IV remain at the same level (19.1%) but result of treatment has not been remarkably improved during last 30 years. Therefore, efforts should be made to improve the therapeutic results in advanced cancer as well as in early cancer. In addition, maintenance of functions, as well as radical treatment, should be taken into consideration. I. Treatment of cervical cancer In Okayama University, treatment for gynecologic malignant tumors has been developed with emphasis on cervical cancer. Now clinical problems are reviewed from retrospective study of cervical cancer treated for 50 years. From 1934, when Dr. Yagi took office as the professor, to end of 1987, 10,587 cases of cervical cancer, including 788 cases of the disease at Stage 0, were treated during the period of 54 years.(ABSTRACT TRUNCATED AT 250 WORDS)
Sekiba
K
K
Department of Obstetrics and Gynecology, Okayama University Medical School.
D000970:Antineoplastic Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003452:Cryosurgery; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods; D007261:Infusions, Intra-Arterial; D011300:Preoperative Care; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000628:therapy
D000970:Antineoplastic Agents